A cysteine enzyme hemostat for efficient heparin-tolerant blood coagulation.
J Mater Chem B
; 11(5): 1079-1089, 2023 02 01.
Article
en En
| MEDLINE
| ID: mdl-36625414
It is challenging to stop bleeding effectively in patients treated with heparin which leads to enhanced risk of uncontrolled bleeding during operation. Herein, we report an easy-to-use and heparin-tolerant hemostatic agent based on a thrombin-like cysteine enzyme (papain), which catalyzes the hydrolysis of fibrinogen and cross-linking of fibrin clots. A papain-based hemostat with increased procoagulant activity is developed through immobilizing papain on the cellulose carrier, which displays short clotting time in both normal and heparinized plasmas. The excellent hemostatic performance of the papain-based hemostat is further confirmed with reduced hemostatic time and limited blood loss in a mouse tail amputation model, rabbit auricular artery injury model and rat liver injury model, in which a natural coagulation system fails to function on account of heparin. This bio-hemostat has great potential to reverse the effect of heparin and stop topical hemorrhage rapidly in surgical procedures.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Hemostáticos
/
Heparina
Idioma:
En
Revista:
J Mater Chem B
Año:
2023
Tipo del documento:
Article